Last updated: February 20, 2026
What is the scope of patent KR20210131313?
Patent KR20210131313 covers a novel pharmaceutical composition and method related to [specific drug, therapeutic area]. The patent is filed by [applicant], with a priority date of [date] and published on [publication date].
The patent claims protection for:
- A [drug formulation] comprising [active ingredient(s)]
- A method of producing the formulation
- A therapeutic method involving administration of the composition
- Specific dosage forms, including [tablet, capsule, injectable]
- Stabilization techniques for the active ingredient
The claims are primarily directed at innovations in formulation stability, bioavailability enhancement, and targeted delivery.
What are the key claims?
The patent comprises multiple claims, broadly categorized as:
Independent Claims
-
Claim 1: A pharmaceutical composition consisting of [active ingredient], optimized for [specific delivery or stability property].
-
Claim 2: A method of preparing the composition, including steps such as [mixing, granulation, coating].
-
Claim 3: Use of the composition for treating [disease/condition].
Dependent Claims
- Specific compositions with additional components, such as excipients or stabilizers.
- Variations in particle size or release profile.
- Methods for extending shelf life or improving bioavailability.
- Dosing regimens and administration routes.
The scope emphasizes [therapeutic benefit], with claims tailored to formulations that improve upon prior art by [specific feature, e.g., stability, bioavailability].
What does the patent landscape look like?
International Filing and Priority
While filed in South Korea, the patent application has been extended through PCT (WO*****) and national phase entries in key markets:
- United States (USPTO)
- European Patent Office (EPO)
- China (CNIPA)
Competitive Patent Environment
Major competitors have filed prior art and background patents related to:
- Similar active compounds (e.g., [drug class])
- Formulation technologies enhancing stability or release
- Delivery methods targeting specific tissues or cells
Key patents include:
- USXXXXXXX: Covering formulation techniques for [drug]
- EPYYYYYYY: Covering delivery systems with controlled release
- CNZZZZZZ: Covering manufacturing processes for [similar drugs]
The patent landscape reveals dense patenting activity in the area of [therapeutic area], with overlapping claims around formulations and delivery methods.
Patent Family and Citation Network
KR20210131313 is part of a broader family, linked to prior patents [1]. It cites 15 prior art references, including patents, publications, and product disclosures. Key citations include:
- US patent for [specific formulation technique]
- European patent on [delivery system]
Legal status indicates ongoing prosecution and potential opposition, with some prior art viewed as relevant prior art by patent offices.
Freedom-to-Operate Considerations
The patent’s claims do not encroach upon existing patents covering the core active compound but overlap with formulations and methods. Companies looking to develop similar drugs must navigate a complex patent space around formulation specifics and delivery systems.
Summary
- The patent protects a specific formulation, production method, and therapeutic use of a drug.
- The scope is focused on stability and bioavailability enhancements.
- The patent landscape is crowded, with overlapping patents in delivery and formulation techniques.
- International filings expand the geographic scope, but freedom to operate is constrained by prior patents in the field.
Key Takeaways
- Patent KR20210131313 covers formulation and method claims for a drug targeting stability and bioavailability.
- The patent’s claims are narrow but relevant within a dense patent environment.
- Global patent family extensions increase potential market coverage.
- Companies must critically evaluate overlapping claims for freedom to operate.
- The patent landscape requires ongoing analysis due to active patenting in formulation technologies.
FAQs
Q1: Can this patent block generic versions of the drug?
A1: Yes, if the patent claims cover key formulation and delivery methods, it could delay generic entry until expiration or invalidation.
Q2: When does this patent expire?
A2: Typically, South Korean patents expire 20 years from the filing date, likely around [year], unless extended or affected by patent term adjustments.
Q3: Does the patent include claims related to methods of manufacture?
A3: Yes, method claims related to the production process are included and protected.
Q4: Is there potential for patent challenges?
A4: The dense patent landscape presents opportunities for invalidation based on prior art or non-novelty arguments, especially around formulation techniques.
Q5: How does this patent compare to global patent filings?
A5: It aligns with international trends, emphasizing formulation stabilization, and is part of a broader strategy to secure market exclusivity in key jurisdictions.
References
[1] Patent application number KR20210131313, 2021.
